Ernesto Guarin

965 total citations
16 papers, 736 citations indexed

About

Ernesto Guarin is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Ernesto Guarin has authored 16 papers receiving a total of 736 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Ernesto Guarin's work include Melanoma and MAPK Pathways (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and Glycosylation and Glycoproteins Research (2 papers). Ernesto Guarin is often cited by papers focused on Melanoma and MAPK Pathways (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and Glycosylation and Glycoproteins Research (2 papers). Ernesto Guarin collaborates with scholars based in Switzerland, United Kingdom and France. Ernesto Guarin's co-authors include Patrick Nef, Michel Dubois‐Dauphin, Fabienne de Bilbao, Atsushi Kuhara, Tamás Bartfai, Edouard de Castro, Hiroyuki Sasakura, Marie Gomez, Ikue Mori and Cornelia I. Bargmann and has published in prestigious journals such as Neuron, Journal of Clinical Oncology and The Journal of Comparative Neurology.

In The Last Decade

Ernesto Guarin

16 papers receiving 718 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ernesto Guarin Switzerland 10 439 214 152 102 87 16 736
Weijia Dong Canada 15 362 0.8× 100 0.5× 169 1.1× 140 1.4× 146 1.7× 17 752
Luca Tiberi Italy 17 857 2.0× 248 1.2× 156 1.0× 90 0.9× 128 1.5× 28 1.2k
Hamid Dolatshad United Kingdom 16 549 1.3× 103 0.5× 79 0.5× 38 0.4× 106 1.2× 25 1.0k
Laure Debure France 13 395 0.9× 153 0.7× 99 0.7× 65 0.6× 113 1.3× 18 617
Konstantin Adamsky Israel 17 681 1.6× 157 0.7× 171 1.1× 116 1.1× 124 1.4× 25 1.3k
Dena S. Leeman United States 11 1.2k 2.7× 178 0.8× 117 0.8× 97 1.0× 220 2.5× 15 2.0k
Katia Carmine-Simmen Canada 9 343 0.8× 139 0.6× 64 0.4× 178 1.7× 71 0.8× 12 701
Pauline Gosselin Switzerland 9 534 1.2× 404 1.9× 60 0.4× 168 1.6× 48 0.6× 16 1.1k
Jelena Mojsilovic‐Petrovic United States 13 575 1.3× 199 0.9× 225 1.5× 76 0.7× 73 0.8× 17 1.1k
B. Morse United States 11 1.1k 2.5× 137 0.6× 185 1.2× 160 1.6× 271 3.1× 13 1.5k

Countries citing papers authored by Ernesto Guarin

Since Specialization
Citations

This map shows the geographic impact of Ernesto Guarin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ernesto Guarin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ernesto Guarin more than expected).

Fields of papers citing papers by Ernesto Guarin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ernesto Guarin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ernesto Guarin. The network helps show where Ernesto Guarin may publish in the future.

Co-authorship network of co-authors of Ernesto Guarin

This figure shows the co-authorship network connecting the top 25 collaborators of Ernesto Guarin. A scholar is included among the top collaborators of Ernesto Guarin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ernesto Guarin. Ernesto Guarin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
García‐Velloso, María José, Iván Peñuelas, Mariano Ponz‐Sarvisé, et al.. (2020). 286 Tumor targeting and tissue biodistribution of RO7122290, a novel FAP-targeted 4–1BB (CD137) agonist, in patients with advanced solid tumors, using [89Zr]-RO7122290 as a PET tracer. Regular and Young Investigator Award Abstracts. A175.1–A175. 4 indexed citations
2.
3.
Brummelen, Emilie M.J. van, Tapan K. Nayak, Marc C. Huisman, et al.. (2016). 89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation in a dose-dependent manner and role of IL-2 receptor-binding. Annals of Oncology. 27. vi114–vi114. 3 indexed citations
4.
Vey, Norbert, Jacques Delaunay, Giovanni Martinelli, et al.. (2016). Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. Oncotarget. 7(22). 32532–32542. 73 indexed citations
5.
Oordt, C. Willemien Menke‐van der Houven van, Carlos Gomez-Roca, Carla van Herpen, et al.. (2016). First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. Oncotarget. 7(48). 80046–80058. 113 indexed citations
6.
Zimmer, Lisa, Fabrice Barlési, Maria Martinez‐García, et al.. (2014). Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations. Clinical Cancer Research. 20(16). 4251–4261. 59 indexed citations
7.
Martinez‐García, Maria, Udai Banerji, Joan Albanell, et al.. (2012). First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors. Clinical Cancer Research. 18(17). 4806–4819. 122 indexed citations
8.
Dolly, Saoirse, Joan Albanell, Françoise Kraeber‐Bodéré, et al.. (2011). First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3006–3006. 4 indexed citations
9.
Soria, J.C., Udai Banerji, Ratislav Bahleda, et al.. (2010). 365 First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumour. European Journal of Cancer Supplements. 8(7). 115–116. 1 indexed citations
10.
Conte, Caroline, Ernesto Guarin, Anne Marcuz, & Pedro J. Andrés-Barquin. (2006). Functional expression of mammalian bitter taste receptors in Caenorhabditis elegans. Biochimie. 88(7). 801–806. 9 indexed citations
11.
Milani, N., Ernesto Guarin, Eduard Renfer, Patrick Nef, & Pedro J. Andrés-Barquin. (2002). Functional expression of a mammalian olfactory receptor in Caenorhabditis elegans. Neuroreport. 13(18). 2515–2520. 8 indexed citations
12.
Gomez, Marie, Edouard de Castro, Ernesto Guarin, et al.. (2001). Ca2+ Signaling via the Neuronal Calcium Sensor-1 Regulates Associative Learning and Memory in C. elegans. Neuron. 30(1). 241–248. 190 indexed citations
13.
Bilbao, Fabienne de, Ernesto Guarin, Patrick Nef, et al.. (2000). Cell death is prevented in thalamic fields but not in injured neocortical areas after permanent focal ischaemia in mice overexpressing the anti‐apoptotic protein Bcl‐2. European Journal of Neuroscience. 12(3). 921–934. 46 indexed citations
14.
Bilbao, Fabienne de, Ernesto Guarin, Patrick Nef, et al.. (1999). Postnatal distribution ofcpp32/caspase 3 mRNA in the mouse central nervous system: An in situ hybridization study. The Journal of Comparative Neurology. 409(3). 339–357. 68 indexed citations
15.
Guarin, Ernesto, et al.. (1999). cpp32 messenger RNA neosynthesis is induced by fatal axotomy and is not regulated by athanatal Bcl-2 over-expression. Neuroscience. 90(2). 653–664. 15 indexed citations
16.
Bilbao, Fabienne de, Ernesto Guarin, Patrick Nef, & Michel Dubois‐Dauphin. (1999). The mouse cpp32 mRNA transcript is early up-regulated in axotomized motoneurons following facial nerve transection. Neuroscience Letters. 266(1). 65–68. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Weijia Dong Breakdown of academic impact, for papers by Luca Tiberi Breakdown of academic impact, for papers by Hamid Dolatshad Breakdown of academic impact, for papers by Laure Debure Breakdown of academic impact, for papers by Konstantin Adamsky Breakdown of academic impact, for papers by Dena S. Leeman Breakdown of academic impact, for papers by Katia Carmine-Simmen Breakdown of academic impact, for papers by Pauline Gosselin Breakdown of academic impact, for papers by Jelena Mojsilovic‐Petrovic Breakdown of academic impact, for papers by B. Morse
Rankless by CCL
2026